Shital Kamble
About
Shital Kamble is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Surgery.
According to data from OpenAlex, Shital Kamble has authored 36 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cardiology and Cardiovascular Medicine, 8 papers in Oncology and 7 papers in Surgery. Recurrent topics in Shital Kamble's work include Atrial Fibrillation Management and Outcomes (9 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Shital Kamble is often cited by papers focused on Atrial Fibrillation Management and Outcomes (9 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). Shital Kamble collaborates with scholars based in United States, United Kingdom and France. Shital Kamble's co-authors include Rebecca A. Moss, Thierry André, Michael J. Overman, Fabio Gelsomino, Bart Neyns, Scott Kopetz, Massimo Aglietta, Ray McDermott, Eric Van Cutsem and Z. Alexander Cao and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.
In The Last Decade
Shital Kamble
34 papers receiving 2.3k citations
Hit Papers
Peers
Shital Kamble
Tyler Zemla United States
Smith Giri United States
Jamey Skillings Canada
Rodolfo Passalacqua Italy
Som D. Mukherjee Canada
Xiaolei Zhu China
Norbert Marschner Germany
Michael H. Torosian United States
Kevin G. Billingsley United States
Jose Alejandro Rauh‐Hain United States
Citations per year, relative to Shital Kamble Shital Kamble (= 1×)
peers
Tyler Zemla
Countries citing papers authored by Shital Kamble
Since
Specialization
Citations
This map shows the geographic impact of Shital Kamble's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shital Kamble with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shital Kamble more than expected).
Fields of papers citing papers by Shital Kamble
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Shital Kamble. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shital Kamble. The network helps show where Shital Kamble may publish in the future.
Co-authorship network of co-authors of Shital Kamble
This figure shows the co-authorship network connecting the top 25 collaborators of Shital Kamble. A scholar is included among the top collaborators of Shital Kamble based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shital Kamble. Shital Kamble is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schuler, Tammy A., et al.. (2025). Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States. Future Oncology. 21(3). 313–319.
2.
Qin, Shukui, Weijia Fang, Zhenggang Ren, et al.. (2024). A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394. Liver Cancer. 13(4). 389–400.
3.
Mehta, Neil, Shital Kamble, Yan Song, et al.. (2024). Real-world correlation of RFS and OS in early-stage hepatocellular carcinoma treated with curative intent: A retrospective analysis of SEER-Medicare data.. Journal of Clinical Oncology. 42(3_suppl). 451–451.
4.
Wang, Liya, Adriana Valderrama, Bal Nepal, et al.. (2024). Real-world treatment patterns, resource utilization and costs in biliary tract cancers in the USA. Future Oncology. 20(34). 2625–2636.
5.
Yoo, Changhoon, Richard S. Finn, Heinz‐Josef Klümpen, et al.. (2023). Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).. Journal of Clinical Oncology. 41(16_suppl). 4003–4003.
6.
Overman, Michael J., Sara Lonardi, Ka Yeung Mark Wong, et al.. (2018). Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer. Journal of Clinical Oncology. 36(8). 773–779.
7.
Lip, Gregory Y.H., Xianying Pan, Shital Kamble, et al.. (2018). Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban. PLoS ONE. 13(4). e0195950–e0195950.
8.
Tepper, Ping G., Jack Mardekian, Cristina Masseria, et al.. (2018). Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS ONE. 13(11). e0205989–e0205989.
9.
André, Thierry, Sara Lonardi, Mark Wong, et al.. (2018). Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.. Journal of Clinical Oncology. 36(4_suppl). 553–553.
10.
Overman, Michael J., Shital Kamble, Rebecca A. Moss, et al.. (2017). Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142. Annals of Oncology. 28. iii107–iii108.
11.
Lip, Gregory Y.H., Xianying Pan, Shital Kamble, et al.. (2016). Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States. International Journal of Clinical Practice. 70(9). 752–763.
12.
Horblyuk, Ruslan, Jack Mardekian, Sang Hee Park, et al.. (2016). Abstract 13828: Real World Bleeding Risks in Non-valvular Atrial Fibrillation Patients With Heart Failure: Contemporary EHR Results Among Prescribed Apixaban, Dabigatran, Rivaroxaban and Warfarin. Circulation. 134(suppl_1).
13.
Lip, Gregory Y.H., Allison Keshishian, Shital Kamble, et al.. (2016). REAL WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON APIXABAN, WARFARIN, DABIGATRAN OR RIVAROXABAN: A 1:1 PROPENSITY-SCORE MATCHED ANALYSIS. Journal of the American College of Cardiology. 67(13). 882–882.
14.
Tepper, Ping G., Jack Mardekian, Cristina Masseria, et al.. (2016). REAL-WORLD COMPARISON OF INPATIENT BLEEDING RISK, BLEEDING-RELATED HOSPITALIZATION RATES AND COSTS AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS ON APIXABAN, DABIGATRAN, RIVAROXABAN: COHORTS COMPRISING NEW INITIATORS AND/OR SWITCHERS FROM WARFARIN. Journal of the American College of Cardiology. 67(13). 662–662.
15.
Keshishian, Allison, Shital Kamble, Xianying Pan, et al.. (2016). Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thrombosis and Haemostasis. 116(11). 975–986.
16.
Lis, Y., Melissa Roberts, Shital Kamble, Jeff J. Guo, & Dennis W. Raisch. (2012). Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals: Report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working Group. Value in Health. 15(8). 1108–1118.
17.
Blanchette, Christopher M., et al.. (2010). Quarterly Assessment of Short-Acting β2-Adrenergic Agonist Use as a Predictor of Subsequent Health Care Use for Asthmatic Patients in the United States. Journal of Asthma. 47(6). 660–666.
18.
Studnicki, James, John W. Fisher, & Shital Kamble. (2010). Race-Differentiated Outcomes in Multiple Special Healthcare Taxing Districts. American Journal of Preventive Medicine. 38(3). 311–316.
19.
Kamble, Shital & Murtuza Bharmal. (2009). Incremental Direct Expenditure of Treating Asthma in the United States. Journal of Asthma. 46(1). 73–80.
20.
Bao, Yuhua & Shital Kamble. (2009). Geographical Distribution of Surgical Capabilities and Disparities in the Use of High-Volume Providers. Medical Care. 47(7). 794–802.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tyler Zemla Breakdown of academic impact, for papers by Smith Giri Breakdown of academic impact, for papers by Jamey Skillings Breakdown of academic impact, for papers by Rodolfo Passalacqua Breakdown of academic impact, for papers by Som D. Mukherjee Breakdown of academic impact, for papers by Xiaolei Zhu Breakdown of academic impact, for papers by Norbert Marschner Breakdown of academic impact, for papers by Michael H. Torosian Breakdown of academic impact, for papers by Kevin G. Billingsley Breakdown of academic impact, for papers by Jose Alejandro Rauh‐Hain